Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
Erasmus MC start fase I/II-studie met innovatieve immuuntherapie bij melanoom
mrt 2022 | Dermato-oncologie, Hoofd-halsoncologie, Immuuntherapie